The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 17, 2017.
Transcript:
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are our top 5 biosimilars articles for the week of July 17:
Number 5: A new report shows that most US-based health plans now cover at least 1 of the 2 available FDA-approved biosimilars.
Number 4: A phase 3 trial of the proposed rituximab biosimilar candidate GP2013 shows positive results in patients with follicular lymphoma.
Number 3: Molly Billstein Leber, manager of Medication Policy and Formulary Management for the Yale New Haven Health System, discusses the FDA’s Oncologic Drugs Advisory Committee’s unanimous recommendation of approval for biosimilars to Avastin and Herceptin.
Number 2: At this week’s public meeting on the Hatch-Waxman Amendments, FDA Commissioner Dr Scott Gottlieb announced the upcoming publication of 2 documents related to the ANDA process.
And finally, Number 1: The FDA Reauthorization Act may proceed to a Senate vote sooner rather than later after the failure of the Better Care Reconciliation Act.
Read these articles and more at centerforbiosimilars.com
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.